Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy.

ABSTRACT:

Background

Sarcopenia is a geriatric syndrome that is characterized by the gradual muscle loss and frailty in the elderly. Meanwhile, the prevalence of prostate cancer is on the rise worldwide. Mainstay treatments for metastatic prostate cancer are androgen-deprivation therapy and taxane-based chemotherapy. Owing to the indolent nature of prostate cancer, these treatments tend to be long-lasting, giving rise to the problem of tolerance to the treatments. Especially given the fact that long-term chemotherapy is closely associated with muscle loss, we aimed to elucidate the correlation between chemotherapy and sarcopenia in the clinical setting.

Materials and methods

This study was a retrospective study. Participants with castration-resistant prostate cancer were recruited fro

SUBMITTER: Ohtaka A 

PROVIDER: S-EPMC6424678 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature